Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $946.0 million.

  • TransMedics' Liabilities and Shareholders Equity rose 2042.6% to $946.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 billion, marking a year-over-year increase of 1695.12%. This contributed to the annual value of $804.1 million for FY2024, which is 1388.42% up from last year.
  • Per TransMedics' latest filing, its Liabilities and Shareholders Equity stood at $946.0 million for Q3 2025, which was up 2042.6% from $890.5 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Liabilities and Shareholders Equity peaked at $946.0 million during Q3 2025, and registered a low of $117.3 million during Q2 2022.
  • In the last 5 years, TransMedics' Liabilities and Shareholders Equity had a median value of $689.2 million in 2023 and averaged $498.1 million.
  • In the last 5 years, TransMedics' Liabilities and Shareholders Equity crashed by 1768.49% in 2021 and then skyrocketed by 48861.58% in 2023.
  • Quarter analysis of 5 years shows TransMedics' Liabilities and Shareholders Equity stood at $134.9 million in 2021, then soared by 105.46% to $277.1 million in 2022, then skyrocketed by 154.76% to $706.0 million in 2023, then grew by 13.88% to $804.1 million in 2024, then increased by 17.65% to $946.0 million in 2025.
  • Its last three reported values are $946.0 million in Q3 2025, $890.5 million for Q2 2025, and $837.5 million during Q1 2025.